

# 6-Mercaptopurine hydrate

Catalog No: tcsc8139



## Available Sizes

**Size:** 50mg

**Size:** 100mg

**Size:** 500mg



## Specifications

**CAS No:**

6112-76-1

**Formula:**

$C_5H_6N_4OS$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

Nucleoside Antimetabolite/Analog

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 32 mg/mL (188.03 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

170.19


## Product Description

6-Mercaptopurine hydrate is a purine analogue which acts as an antagonist of the **endogenous purines** and has been widely used as antileukemic agent and immunosuppressive drug.

IC50 & Target: endogenous purines<sup>[1]</sup>

**In Vitro:** 6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P[2]).

**In Vivo:** In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returns to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!